BlackRock
CLYM

BlackRock’s Climb Bio CLYM Stock Holding History

BlackRock’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.75M Buy
401,649
+12,340
+3% +$71.2K ﹤0.01% 4035
2025
Q4 		$1.56M Sell
389,309
-346,194
-47% -$831K ﹤0.01% 4190
2025
Q3 		$1.48M Sell
735,503
-142,466
-16% -$265K ﹤0.01% 4188
2025
Q2 		$1.09M Sell
877,969
-1,418,455
-62% -$1.77M ﹤0.01% 4226
2025
Q1 		$2.8M Sell
2,296,424
-9,831
-0.4% -$15.9K ﹤0.01% 3885
2024
Q4 		$4.15M Buy
2,306,255
+439,158
+24% +$1.59M ﹤0.01% 3802
2024
Q3 		$9.5M Buy
1,867,097
+1,485,374
+389% +$10.5M ﹤0.01% 3435
2024
Q2 		$2.71M Buy
381,723
+351,283
+1,154% +$2.34M ﹤0.01% 3881
2024
Q1 		$83.4K Sell
30,440
-705
-2% -$1.94K ﹤0.01% 4774
2023
Q4 		$84.1K Sell
31,145
-166
-0.5% -$432 ﹤0.01% 4854
2023
Q3 		$82.3K Sell
31,311
-581
-2% -$1.58K ﹤0.01% 4906
2023
Q2 		$89.3K Sell
31,892
-809
-2% -$2.46K ﹤0.01% 4949
2023
Q1 		$94.8K Buy
32,701
+498
+2% +$1.71K ﹤0.01% 4969
2022
Q4 		$118K Buy
32,203
+332
+1% +$985 ﹤0.01% 4988
2022
Q3 		$102K Sell
31,871
-415
-1% -$1.32K ﹤0.01% 5169
2022
Q2 		$97K Sell
32,286
-307,059
-90% -$1.45M ﹤0.01% 5250
2022
Q1 		$2.85M Sell
339,345
-17,099
-5% -$160K ﹤0.01% 4238
2021
Q4 		$3.73M Buy
356,444
+24,318
+7% +$363K ﹤0.01% 4127
2021
Q3 		$5.97M Buy
+332,126
New +$6.86M ﹤0.01% 3888

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

BlackRock's CLYM Position: Q1 2026 in Review

BlackRock increased its Climb Bio (CLYM) stake by 3.2% in Q1 2026, buying an estimated $71.2K and bringing the position to 401,649 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4035.

BlackRock first reported a position in CLYM in Q3 2021 and has held it in 19 quarters since. The position peaked at $9.5M in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • BlackRock held 401,649 shares of Climb Bio worth $2.75M as of Q1 2026.
  • BlackRock bought 12,340 Climb Bio shares in Q1 2026, an estimated $71.2K.
  • Climb Bio made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4035 holding.
  • BlackRock first reported a position in Climb Bio in Q3 2021 and has held it in 19 quarters since.
  • BlackRock's Climb Bio position peaked at $9.5M in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.